Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech

Executive Summary

Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.

Advertisement

Related Content

Device/Diagnostics Quarterly Deal Statistics, Q3 2016
Pacts In Medtech, July/August 2016
In Vivo's Deals Of The Month, August 2016
Google Broadens Diabetes Reach With Dexcom Partnership
Google and Novartis in smart lens pact
GSK pumps $50m into new-gen neuromodulation techs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register